Retatrutide hitting three targets sets a wild new bar for weight loss data
Posted by kayla270 in Research & News - 1 points, 0 comments.
Lilly's retatrutide just posted results where people lost around 30% of their body weight on average, which is higher than what we saw with tirzepatide and semaglutide in their big trials. The interesting part is that it is hitting GLP-1, GIP, and glucagon receptors all at once, so it is basically stacking three hormone signals into one weekly shot.
What gets me is how fast the bar keeps moving. A few years ago 10% weight loss felt like a breakthrough, and now we are talking about numbers that get close to what bariatric surgery does, but with a peptide you inject at home. I am curious what the muscle mass picture looks like over a year or two, because losing that much weight fast usually comes with some lean tissue loss too, and nobody really talks about that.
For anyone watching this space, do you think a triple agonist like this is genuinely safer long term than stacking lower dose GLP-1s, or is it just more efficient at doing the same thing?
Community discussion - research and educational context only. Not medical advice.